NCT00062647

Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

A Phase 2, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Televancin (TD-6424) for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Cumberland Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.

Conditions

• Gram-Positive Bacterial Infections

Interventions

Type	Name	Description
DRUG	Telavancin	Telavancin 10mg/kg/day IV every 24 hrs for up to 14 days
DRUG	Vancomycin, nafcillin, oxacillin, or cloxacillin	Vancomycin 1 Gram every 12 hr IV (intravenously) OR nafcillin, oxacillin, or cloxacillin 2 Grams every 6 hr IV (intravenously) for up to 14 days.

Timeline

• Start date: 2003-08-01
• Primary completion: 2006-08-01
• Completion: 2006-08-01
• First posted: 2003-06-12
• Last updated: 2019-01-16
• Results posted: 2011-03-22

Locations

1 site across 1 country: United States